Birdwatch Note
2023-04-16 21:43:29 UTC - NOT_MISLEADING
The Tweet doesn't claim that Ivermectin has efficacy in treating COVID-19, it indicates that it MAY have efficacy due to its antiviral properties and proven human safety profile. https://europepmc.org/article/MED/32942671
Written by 24C1B62119D4440FF2F4959B3645109A100EB1E073EC7A78C425A9BE71B57415
Participant Details
Original Tweet
Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1647658944469319681
Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.
All Information
- ID - 1647717371136860160
- noteId - 1647717371136860160
- participantId -
- noteAuthorParticipantId - 24C1B62119D4440FF2F4959B3645109A100EB1E073EC7A78C425A9BE71B57415 Participant Details
- createdAtMillis - 1681681409045
- tweetId - 1647658944469319681
- classification - NOT_MISLEADING
- believable -
- harmful -
- validationDifficulty -
- misleadingOther - 0
- misleadingFactualError - 0
- misleadingManipulatedMedia - 0
- misleadingOutdatedInformation - 0
- misleadingMissingImportantContext - 0
- misleadingUnverifiedClaimAsFact - 0
- misleadingSatire - 0
- notMisleadingOther - 0
- notMisleadingFactuallyCorrect - 1
- notMisleadingOutdatedButNotWhenWritten - 0
- notMisleadingClearlySatire - 0
- notMisleadingPersonalOpinion - 0
- trustworthySources - 1
- summary
- The Tweet doesn't claim that Ivermectin has efficacy in treating COVID-19, it indicates that it MAY have efficacy due to its antiviral properties and proven human safety profile. https://europepmc.org/article/MED/32942671
Note Ratings
| rated at | rated by | |
| 2023-05-09 13:17:15 -0500 | Rating Details | |
| 2023-04-16 18:28:28 -0500 | Rating Details | |
| 2023-04-16 17:58:43 -0500 | Rating Details | |
| 2023-04-16 19:15:02 -0500 | Rating Details | |
| 2023-04-16 19:45:46 -0500 | Rating Details | |
| 2023-04-16 19:38:15 -0500 | Rating Details | |
| 2023-04-16 22:43:13 -0500 | Rating Details | |
| 2023-04-16 17:29:11 -0500 | Rating Details | |
| 2023-04-16 18:09:26 -0500 | Rating Details | |
| 2023-04-16 20:17:54 -0500 | Rating Details | |
| 2023-04-16 19:41:09 -0500 | Rating Details | |
| 2023-04-16 18:37:21 -0500 | Rating Details | |
| 2023-04-16 17:50:30 -0500 | Rating Details | |
| 2023-04-16 18:23:54 -0500 | Rating Details | |
| 2023-04-16 17:55:03 -0500 | Rating Details | |
| 2023-04-16 19:25:33 -0500 | Rating Details | |
| 2023-04-16 17:03:21 -0500 | Rating Details | |
| 2023-04-17 00:39:36 -0500 | Rating Details | |
| 2023-04-16 17:20:54 -0500 | Rating Details | |
| 2023-04-16 18:28:28 -0500 | Rating Details | |
| 2023-04-16 17:58:43 -0500 | Rating Details | |
| 2023-04-16 19:15:02 -0500 | Rating Details | |
| 2023-04-16 19:45:46 -0500 | Rating Details | |
| 2023-04-16 19:38:15 -0500 | Rating Details | |
| 2023-04-16 22:43:13 -0500 | Rating Details | |
| 2023-04-16 17:29:11 -0500 | Rating Details | |
| 2023-04-16 18:09:26 -0500 | Rating Details | |
| 2023-04-16 20:17:54 -0500 | Rating Details | |
| 2023-04-16 19:41:09 -0500 | Rating Details | |
| 2023-04-16 18:37:21 -0500 | Rating Details | |
| 2023-04-16 17:50:30 -0500 | Rating Details | |
| 2023-04-16 18:23:54 -0500 | Rating Details | |
| 2023-04-16 17:55:03 -0500 | Rating Details | |
| 2023-05-09 13:17:15 -0500 | Rating Details | |
| 2023-04-16 19:25:33 -0500 | Rating Details | |
| 2023-04-16 17:03:21 -0500 | Rating Details | |
| 2023-04-17 00:39:36 -0500 | Rating Details | |
| 2023-04-16 17:20:54 -0500 | Rating Details |